World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00541073
Date of registration: 05/10/2007
Prospective Registration: No
Primary sponsor: Centre Oscar Lambret
Public title: Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
Scientific title: Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma
Date of first enrolment: June 2007
Target sample size: 60
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00541073
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
France
Contacts
Name:     Amelie Lansiaux, MD, PhD
Address: 
Telephone:
Email:
Affiliation:  Centre Oscar Lambret
Key inclusion & exclusion criteria

DISEASE CHARACTERISTICS:

Inclusion criteria:

- Histologically confirmed pleural mesothelioma

- Unresectable disease

Exclusion criteria:

- Clinically detected pleural effusion or ascites that cannot be controlled by drainage
or other procedures

PATIENT CHARACTERISTICS:

Inclusion criteria:

- WHO performance status 0-2

- Life expectancy > 3 months

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Creatinine clearance > 45 mL/min

- Total bilirubin = 1.5 times upper limit of normal (ULN)

- Transaminases = 3 times ULN (5 times ULN if liver metastases)

- Not pregnant or nursing

- Fertile patients of must use effective contraception during and for 6 months after
completion of study treatment

Exclusion criteria:

- Hypersensitivity to pemetrexed disodium or any of its excipients

- Peripheral neuropathy = grade 2

- Impossible to receive study therapy due to geographical, social, familial, or
psychological reasons

PRIOR CONCURRENT THERAPY:

Inclusion criteria:

- At least 28 days since prior radiotherapy (21 days for injected radiotherapy)

Exclusion criteria:

- Prior chemotherapy

- Prior yellow fever vaccine

- Inability to discontinue aspirin (> 1.3 g/day) or NSAIDs for 2 days prior to, during,
and 2 days after day 1 of each course of study therapy

- Concurrent participation in another clinical study



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Malignant Mesothelioma
Intervention(s)
Drug: pemetrexed disodium
Other: laboratory biomarker analysis
Drug: cisplatin
Other: pharmacological study
Dietary Supplement: vitamin B12
Genetic: gene expression analysis
Primary Outcome(s)
Individual dosage-adapted protocol [Time Frame: No]
Secondary Outcome(s)
Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD) [Time Frame: No]
Relationship between pharmacokinetic and pharmacodynamic parameters [Time Frame: No]
Pharmacokinetics [Time Frame: No]
Secondary ID(s)
COL-ALIMESO
COL-2006-04
CDR0000564058
INCA-RECF0441
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history